Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014, Article ID 738428, 6 pages
http://dx.doi.org/10.1155/2014/738428
Case Report

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder

1Rutgers-NJMS, The State University of New Jersey, Newark, NJ 07103, USA
2Hackensack University Medical Center, Hackensack, NJ 07601, USA
3Regional Cancer Care Associates, Freehold, NJ 07728, USA

Received 17 July 2014; Accepted 29 September 2014; Published 15 October 2014

Academic Editor: Marie-Christine Kyrtsonis

Copyright © 2014 J. Maerki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Ragupathi, V. Najfeld, A. Chari, B. Peterson, S. Jaqannath, and J. Mascarenhas, “A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature,” Clinical Lymphoma Myeloma and Leukemia, vol. 13, no. 2, pp. 175–179, 2013. View at Publisher · View at Google Scholar
  2. M. Tanaka, R. Kimura, A. Matsutani, K. Zaitsu, Y. Oka, and K. Oizumi, “Coexistence of chronic myelogenous leukemia and multiple myeloma,” Acta Haematologica, vol. 99, no. 4, pp. 221–223, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Derghazarian and N. B. Whittemore, “Multiple myeloma superimposed on chronic myelocytic leukemia,” Canadian Medical Association Journal, vol. 110, no. 9, pp. 1047–1050, 1974. View at Google Scholar · View at Scopus
  4. M. A. Boots and G. D. Pegrum, “Simultaneous presentation of chronic granulocytic leukaemia and multiple myeloma,” Journal of Clinical Pathology, vol. 35, no. 3, pp. 364–365, 1982. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Galanopoulos, S. I. Papadhimitriou, E. Kritikou-Griva, M. Georgiakaki, and N. I. Anagnostopoulos, “Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia,” Annals of Hematology, vol. 88, no. 3, pp. 281–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Schwarzmeier, M. Shehata, J. Ackermann, M. Hilgarth, H. Kaufmann, and J. Drach, “Simultaneous occurrence of chronic myeloid leukemia and multiple myeloma: evaluation by FISH analysis and in vitro expansion of bone marrow cells,” Leukemia, vol. 17, no. 7, pp. 1426–1428, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Alvarez-Larrán, M. Rozman, and F. Cervantes, “Simultaneous occurrence of multiple myeloma and chronic myeloid leukemia,” Haematologica, vol. 86, no. 8, p. 894, 2001. View at Google Scholar · View at Scopus
  8. M. Ide, N. Kuwahara, E. Matsuishi, S. Kimura, and H. Gondo, “Uncommon case of chronic myeloid leukemia with multiple myeloma,” International Journal of Hematology, vol. 91, no. 4, pp. 699–704, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Michael, M. Antoniades, E. Lemesiou, N. Papaminas, and F. Melanthiou, “Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months,” Oncologist, vol. 14, no. 12, pp. 1198–1200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Garipidou, S. Vakalopoulou, and K. Tziomalos, “Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate,” Oncologist, vol. 10, no. 6, pp. 457–458, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Nitta, K. Tsuboi, S. Yamashita et al., “Multiple myeloma preceding the development of chronic myelogenous leukemia,” International Journal of Hematology, vol. 69, no. 3, pp. 170–173, 1999. View at Google Scholar · View at Scopus
  12. P. J. Klenn, B. H. Hyun, Y. H. Lee, and W. Y. Zheng, “Multiple myeloma and chronic myelogenous leukemia—a case report with literature review,” Yonsei Medical Journal, vol. 34, no. 3, pp. 293–300, 1993. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. MacSween and G. R. Langley, “Light-chain disease (hypogammaglobulinemia and Bence Jones proteinuria) and sideroblastic anemia—preleukemic chronic granulocytic leukemia,” Canadian Medical Association Journal, vol. 106, no. 9, pp. 995–998, 1972. View at Google Scholar · View at Scopus
  14. N. A. Romanenko, S. S. Bessmel’tsev, V. I. Udal’eva et al., “The combination of chronic myeloid leukemia and multiple myeloma in one patient,” Voprosy Onkologii, vol. 59, no. 2, pp. 103–110, 2013. View at Google Scholar · View at Scopus
  15. C. Offiah, P. T. Murphy, J. P. Quinn, and P. Thornton, “Co-existing chronic myeloid leukaemia and multiple myeloma: rapid response to lenalidomide during imatinib treatment,” International Journal of Hematology, vol. 95, no. 4, pp. 451–452, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Steinhoff, C. Assaf, I. Anagnostopoulos, C. C. Geilen, H. Stein, and M. Hummel, “Three coexisting lymphomas in one patient: genetically related or only a coincidence?” Journal of Clinical Pathology, vol. 59, no. 12, pp. 1312–1315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Thomas, S. Mailankody, N. Korde, S. Y. Kristinsson, I. Turesson, and O. Landgren, “Second malignancies after multiple myeloma: From 1960s to 2010s,” Blood, vol. 119, no. 12, pp. 2731–2737, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. L. B. Travis, C. S. Rabkin, L. M. Brown et al., “Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations,” Journal of the National Cancer Institute, vol. 98, no. 1, pp. 15–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. W. E. Evans and H. L. McLeod, “Pharmacogenomics—drug disposition, drug targets, and side effects,” The New England Journal of Medicine, vol. 348, no. 6, pp. 538–549, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Allan and L. B. Travis, “Mechanisms of therapy-related carcinogenesis,” Nature Reviews Cancer, vol. 5, no. 12, pp. 943–955, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. G. D. Friedman and L. J. Herrinton, “Obesity and multiple myeloma,” Cancer Causes and Control, vol. 5, no. 5, pp. 479–483, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Landgren, S. V. Rajkumar, R. M. Pfeiffer et al., “Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women,” Blood, vol. 116, no. 7, pp. 1056–1059, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. L. M. Brown, G. Gridley, D. Check, and O. Landgren, “Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders,” Blood, vol. 111, no. 7, pp. 3388–3394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Y. Kristinsson, L. R. Goldin, M. Björkholm, J. Koshiol, I. Turesson, and O. Landgren, “Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies,” Haematologica, vol. 94, no. 11, pp. 1581–1589, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Shimizu, W. J. Schull, and H. Kato, “Cancer risk among atomic bomb survivors. The RERF life span study,” Journal of the American Medical Association, vol. 264, no. 5, pp. 601–604, 1990. View at Publisher · View at Google Scholar · View at Scopus
  26. D. L. Preston, S. Kusumi, M. Tomonaga et al., “Cancer incidence in atomic bomb survivors. Part III: leukemia, lymphoma and multiple myeloma, 1950–1987,” Radiation Research, vol. 137, no. 2 supplement, pp. S68–S97, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Iwanaga, W.-L. Hsu, M. Soda et al., “Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors,” Journal of Clinical Oncology, vol. 29, no. 4, pp. 428–434, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Iwanaga, M. Tagawa, K. Tsukasaki et al., “Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors,” Blood, vol. 113, no. 8, pp. 1639–1650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Landgren, “A role for ionizing radiation in myelomagenesis?” Blood, vol. 113, no. 8, pp. 1616–1617, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. L. S. Gold, P. A. Stewart, K. Milliken et al., “The relationship between multiple myeloma and occupational exposure to six chlorinated solvents,” Occupational and Environmental Medicine, vol. 68, no. 6, pp. 391–399, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Sonoda, T. Ishida, M. Mori, H. Sakai, M. Noguchi, and K. Imai, “A case-control study of multiple myeloma in Japan: association with occupational factors,” Asian Pacific Journal of Cancer Prevention, vol. 6, no. 1, pp. 33–36, 2005. View at Google Scholar · View at Scopus
  32. M. Deininger, E. Buchdunger, and B. J. Druker, “The development of imatinib as a therapeutic agent for chronic myeloid leukemia,” Blood, vol. 105, no. 7, pp. 2640–2653, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Pandiella, X. Carvajal-Vergara, S. Tabera, G. Mateo, N. Gutiérrez, and J. F. San Miguel, “Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents,” British Journal of Haematology, vol. 123, no. 5, pp. 858–868, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Carulli, E. Cannizzo, V. Ottaviano et al., “Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib,” Leukemia Research, vol. 34, no. 10, pp. 1336–1339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. P. Little, H. A. Weiss, J. D. Boice Jr., S. C. Darby, N. E. Day, and C. R. Muirhead, “Risks of leukemia in Japanese atomic bomb survivors, in women treated for cervical cancer, and in patients treated for ankylosing spondylitis,” Radiation Research, vol. 152, no. 3, pp. 280–292, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Holmberg, “Is the primary event in radiation-induced chronic myelogenous leukemia the induction of the t(9;22) translocation?” Leukemia Research, vol. 16, no. 4, pp. 333–336, 1992. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Sakai, M. Kawano, N. Oguma, and A. Kuramoto, “A case of plasma cell leukemia superimposed on Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia,” American Journal of Hematology, vol. 36, no. 3, pp. 222–223, 1991. View at Publisher · View at Google Scholar · View at Scopus
  38. K. N. Manola, D. Pantelidou, and M. Papaioannou, “Plasmablastic crisis of Philadelphia chromosome-positive chronic myeloid leukemia,” Annals of Hematology, vol. 89, no. 6, pp. 641–642, 2009. View at Publisher · View at Google Scholar
  39. M. Tanaka, K. Tanaka, and K. Oizumi, “Coexistence of multiple myeloma and chronic myelogenous leukemia,” International Journal of Hematology, vol. 70, no. 2, pp. 132–133, 1999. View at Google Scholar · View at Scopus
  40. M. Savona and M. Talpaz, “Getting to the stem of chronic myeloid leukaemia,” Nature Reviews Cancer, vol. 8, no. 5, pp. 341–350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. P. J. Martin, V. Najfeld, J. A. Hansen, G. K. Penfold, R. J. Jacobson, and P. J. Fialkow, “Involvement of the B-lymphoid system in chronic myelogenous leukaemia,” Nature, vol. 287, no. 5777, pp. 49–50, 1980. View at Publisher · View at Google Scholar · View at Scopus
  42. H. van den Berghe, A. Louwagie, A. Broeckaert-van Orshoven et al., “Philadelphia chromosome in human multiple myeloma,” Journal of the National Cancer Institute, vol. 63, no. 1, pp. 11–16, 1979. View at Google Scholar
  43. E. Paietta, M. Goldstein, and P. Papenhausen, “Transformation of myeloma into Ph1-negative CML with plasma cell antigens,” The American Journal of Hematology, vol. 19, no. 3, pp. 289–292, 1985. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Guglielmi, F. Davi, and J. C. Brouet, “Prevalence of monoclonal Ig with λ light chains in chronic myelocytic leukaemia,” The British Journal of Haematology, vol. 73, no. 3, pp. 331–333, 1989. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Hideshima, C. Mitsiades, G. Tonon, P. G. Richardson, and K. C. Anderson, “Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets,” Nature Reviews Cancer, vol. 7, no. 8, pp. 585–598, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Mailankody, R. M. Pfeiffer, S. Y. Kristinsson et al., “Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS),” Blood, vol. 118, no. 15, pp. 4086–4092, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. O. Yamada, E. Mahfoudhi, I. Plo et al., “Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone,” Journal of Clinical Oncology, vol. 32, no. 21, pp. e76–e79, 2014. View at Publisher · View at Google Scholar